GLP-1 is a physiological hormone that has multiple actions on glucose, mediated by the GLP-1 receptors. Ozempic® acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1.1
Once-weekly Ozempic® mechanism of action
GLP-1 RA stimulates the body’s own insulin secretion
Ozempic® is a GLP‑1 analogue with 94% sequence homology to human GLP‑11
Structural modifications of the Ozempic® molecule result in decreased renal clearance and protection from metabolic degradation.1
Ozempic® delivers weeklong coverage1
~7 days | Elimination half-life of ~7 days.
4 to 5 weeks
Steady-state plasma concentrations achieved following 4 to 5 weeks of once-weekly administration.
Ozempic® is dosed once weekly
Ozempic® has gradual dose escalation designed to help patients adjust to therapy.1,a Patients should administer Ozempic® once weekly with or without meals.
Text: double click to edit.